Hiberix

Hiberix is a Haemophilus influenzae type b (Hib) conjugate vaccine that contains the active ingredient Haemophilus influenzae type b polysaccharide linked to tetanus toxoid. It is supplied as sterile injectable solution for intramuscular or subcutaneous administration. The product is marketed in the European Union and is available only by prescription. Hiberix is designed to stimulate active immunity against Hib disease, particularly in infants and young children.

Hiberix is indicated for the prevention of invasive disease caused by Haemophilus influenzae type b. It is used as part of routine childhood immunization schedules and may also be given to older children or adults at risk.

- Primary immunization series in infants (typically at 2, 4, and 6 months of age). - Booster dose administered after completion of the primary series. - Immunization of children aged 12–23 months who have not completed the series. - Use in individuals with certain immunodeficiencies who require protection against Hib. - Administration to travelers to regions where Hib disease remains endemic.

Like most injectable vaccines, Hiberix can cause local and systemic reactions, most of which are mild and self‑limited.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever within 24‑48 hours. - Irritability or fussiness in infants. - Mild headache or fatigue.

Serious: - Severe allergic reaction (anaphylaxis) with difficulty breathing or hives. - High fever (>40 °C) or seizures (febrile convulsions).

Healthcare providers should assess individual risk factors before administering Hiberix and observe patients after vaccination.

- Do not administer to persons with a known severe allergy to any vaccine component. - Postpone vaccination in individuals with acute moderate or severe illness until recovery. - Use caution in patients with a history of seizures or febrile convulsions. - Monitor for signs of anaphylaxis for at least 15 minutes after injection. - Discuss with a physician before vaccinating immunocompromised patients. - Consider deferring the vaccine in pregnant women until risk‑benefit is evaluated.

Hiberix has limited known drug interactions, but certain co‑administered agents may require attention.

Avoid: - Live bacterial or viral vaccines administered within 4 weeks (to avoid interference with immune response).

Use with caution: - Immunoglobulin or blood products given within 2 weeks may reduce vaccine efficacy. - Concomitant administration of other childhood vaccines is generally acceptable but observe for additive local reactions. - Antipyretics (e.g., acetaminophen) may be used to manage fever but should not be given prophylactically before vaccination.